Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis

Opinion
Video

Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
1 expert in this video
1 expert in this video
© 2025 MJH Life Sciences

All rights reserved.